HIV-2EU—Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update: Table 1.

To the Editor—In 2013, we published a standardized human immunodeficiency virus type 2 (HIV-2) drug-resistance interpretation in an issue of Clinical Infectious Diseases [1]. This interpretation was defined during an international expert consensus workshop and implemented in an Internet tool (http://www.hiv-grade.de). Over the last 2 years, new data on HIV-2 drug resistance have been presented, particularly for integrase inhibitors and protease inhibitors. Therefore, we decided to update this interpretation. Rules were proposed by each member of the expert panel and subsequently optimized through discussion by considering the following: phenotypic data with HIV-2 site-directed mutants and clinical isolates; data derived from HIV-1 clinical practice; and experience accumulated through the follow-up of HIV-2–infected patients. During this procedure, the latest data published or presented during international conferences were taken into account. Regarding nucleoside reverse transcriptase inhibitors, no major changes have been undertaken, except for the discouragement of stavudine and didanosine use (Table 1).